Background
Methods
Search summary
Inclusion and exclusion standard
Statistical analysis
Results
Study processing
Study, year | Setting | Country | Sample (dead/alive) | Age (dead/alive) | Chronic liver disease (dead/alive) | ALT (dead/alive) | AST (dead/alive) | Female gender | NOS |
---|---|---|---|---|---|---|---|---|---|
Yang et al. [7], 2020 | ICU | China | 32/20 | 64.6 (11.2)/51.9 (12.9) | NA | NA | NA | 11/6 | 7 |
Wang et al. [13], 2020 | Isolation ward | China | 65/274 | 76 (70–83)/68 (64–74) | 1/1 | 24 (19–49)/28 (17–43) | 43 (30–68)/29 (22–43) | 26/147 | 7 |
Chen N et al. [14], 2020 | Isolation ward | China | 113/161 | 68.0(62.0–77.0)/51.0(37.0–66.0) | 5/6 (HBsAg +) | 28.0 (18.0–47.0)/ 20.0 (14.8–32.0) | 45.0 (31.0–67.0)/ 25.0 (20.0–33.3) | 30/73 | 8 |
Zhou et al. [16] 2020 | Isolation ward | China | 54/135 | 69·0 (63·0–76·0)/52·0 (45·0–58·0) | NA | 40.0 (24.0–51.0)/27.0 (15.0–40.0) | NA | 16/56 | 7 |
Du et al. [15], 2020 | Isolation ward | China | 21/158 | 70.2(7.7)/56.0(13.5) | 2/2 | 27.0 (20.0‒37.0)/22.0 (14.0‒40.5) | 40.0 (27.0‒61.5)/27.5 (19.0‒42.0) | 11/71 | 7 |
Study, year | Setting | Country | Sample (non-severe/severe) | Age (non-severe/severe) | Chronic liver disease (non-severe/severe) | ALT (non-severe/severe) | AST (non-severe/severe) | TBIL. (non-severe/severe) | Female | NOS | |
---|---|---|---|---|---|---|---|---|---|---|---|
Chen guang et al. [17], 2020a | Isolation ward | China | 10/11 | 52.0(42.8–56.0)/61.0 (56.5–66.0) | NA | 16.0 (13.3–21.8)/42.0 (32.5–50.0) | 24.0(21.5–26.5)/47.0 (28.0–74.5) | 7.8 (6.4–9.5)/8.8 (7.9–10.5) | 1/3 | 7 | |
Zheng et a. [18], 2020 | Isolation ward | China | 131/30 | 40 (31–51)/57 (46.5–66) | 4/0 | 19.3 (14.6–17.8)/23.9 (17.6–35.3) | 23.4 (19.0–28.8)/31.6 (25.9–49.36) | 10.7 (8.18–15.3)/12.7 (9.2–16.9) | 65/16 | 7 | |
Wan et al. [11], 2020 | Isolation ward | China | 95/40 | 44(33–49)/56(52–73) | 1/1 | 21.7(14.8–36.9)/26.6(14.5–33.3) | 22.4(16.9–30.5)/33.6(25.7–44.2) | 8.6(5.6–14)/9.8(7.8–15.6) | 43/19 | 8 | |
Zhang et al. [19], 2020b | Isolation ward | China | 84/31 | 43.96 ± 14.84/64.58 ± 13.26 | 3/2 (Hepatitis B) | 21.22 ± 12.67/37.87 ± 32.17 | 24.39 ± 9.79/38.87 ± 22.55 | 10.27 ± 4.26/14.12 ± 6.37 | 55/11 | 7 | |
Guan et al. [20], 2020c | Isolation ward | China | 926/173 | 45.0(34.0–57.0)/52.0 (40.0–65.0) | 22/1 (Hepatitis B) | 120/606 vs 38/135 | 112/615 vs 56/142 | 59/594 vs 17/128 | 386/73 | 8 | |
Ji et al. [21], 2020 | Isolation ward | China | 163/39 | 42.9 (32.6 - 51.8)/55.1 (43.7 -71.8) | 42/34 (NAFLD) 5/2 (HBsAg) | 82/163 vs 19/39 | 24/163 vs 10/39 | 13/163 vs 4/39 | 77/12 | 7 | |
Cai et al. [8]. 2020d | Isolation ward | China | 233/85 (A) 47/43 (B) | NA | 78/60 (A) 28/41 (B) | 41 (23–65)/67 (47–100) (A) 84 (42–136)/96 (63–159) (B) | 34(27–45)/58(41–93) (A) 45(29–81)/80(56–145) (B) | 19 (13–26)/22 (18–28) (A) 22 (15–41)/25 (19–32) (B) | NA | 7 | |
Li et al. [10], 2020e | Isolation ward | China | 279/269 | 56 (44–66)/65 (54–72) | 2/2 | 61/275 vs 64/266 | 64/275 vs 115/265 | 7/275 vs 17/266 | 153/116 | 7 |
Pooled analysis
Survivors vs non-survivors
Non-severe vs severe based on ALT, AST and TBIL
Subgroup analysis and sensitivity analysis
Subgroup | Studies sample size | Included (N) (study/control) | Chi-square (df) | P value | Pooled overall heterogeneity | SMD (95% CI) (I2) |
---|---|---|---|---|---|---|
Non-survivors vs survivors ALS (levels) | ||||||
Age≥70 | 2 | 86/432 | 0.72 (1) | .001 | 3.25 (2.95-3.56) | 0 |
Severe vs non-severe ALT (levels) | ||||||
Number of non-severe≥100 | 2 | 115/364 | 0.06 (1) | .001 | 3.42 (3.12-3.73) | 0 |
Severe vs non-severe AST (events) | ||||||
Age≥60 | 6 | 379/1284 | 11.17 (5) | .001 | 5.09 (3.26-7.94) | 55 |
Severe vs non-severe AST (levels) | ||||||
Age≥60 | 3 | 81/236 | 2.21 (2) | .001 | 3.98 (3.54-4.43) | 10 |
Severe vs non-severe TBIL (levels) | ||||||
Number of non-severe≥100 | 2 | 88/364 | 0.62 (1) | .001 | 1.49 (1.24-1.74) | 0 |
Number of non-severe<100 | 4 | 125/236 | 5.14 (3) | .001 | 0.93 (0.61-1.25) | 42 |